Pulmocide Receives $52 Million in Series C+ Financing
Pulmocide is a developer of new drugs for respiratory diseases, focusing on the development of drugs for respiratory diseases. Pulmocide announced it has raised $52 million in an extended Series C round led by new investors Pictet Alternative Advisors and Vivo Capital. Existing investors SV Health Investors, Jeito Capital, SR One, IP Group plc, F-Prime […]
Pulmocide Receives $52 Million in Series C+ Financing Read More »